Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands

Razenberg, L G E M ; van Gestel, Y R B M ; Creemers, G-J ; Verwaal, V J LU ; Lemmens, V E P P and de Hingh, I H J T (2015) In European Journal of Surgical Oncology 41(4). p.71-466
Abstract

BACKGROUND: Population-based data on the percentage of colorectal cancer (CRC) patients with synchronous peritoneal carcinomatosis (PC) being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are currently lacking. The current population-based study describes trends in the use of CRS-HIPEC in the Netherlands, one of the first countries where CRS and HIPEC was introduced.

METHODS: All patients diagnosed with synchronous PC of CRC between 2005 and 2012 were extracted from the Netherlands Cancer Registry (n = 4623). Patients with primary appendiceal cancer were excluded resulting in a study population of 4430 patients. Trends in the use of CRS-HIPEC over time were analyzed by means of a... (More)

BACKGROUND: Population-based data on the percentage of colorectal cancer (CRC) patients with synchronous peritoneal carcinomatosis (PC) being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are currently lacking. The current population-based study describes trends in the use of CRS-HIPEC in the Netherlands, one of the first countries where CRS and HIPEC was introduced.

METHODS: All patients diagnosed with synchronous PC of CRC between 2005 and 2012 were extracted from the Netherlands Cancer Registry (n = 4623). Patients with primary appendiceal cancer were excluded resulting in a study population of 4430 patients. Trends in the use of CRS-HIPEC over time were analyzed by means of a Cochrane-Armitage trend test. Survival proportions were calculated as the time between diagnosis and date of death or last follow-up (January 2014).

RESULTS: Of the total 4430 patients with synchronous PC, 297 (6.4%) underwent treatment with CRS-HIPEC. The proportion of colorectal PC patients receiving CRS-HIPEC increased significantly over time from 3.6% in 2005-2006 to 9.7% in 2011-2012 (p < 0.0001). Overall median survival (MS) for patients treated with CRS-HIPEC was 32.3 months, whereas MS rates were respectively 12.6, 6.1 and 1.5 for months palliative chemotherapy with/without surgery, palliative surgery and best supportive care.

CONCLUSION: The proportion of patients diagnosed with synchronous PC from CRC treated with CRS-HIPEC has increased significantly over time and currently almost 10% of PC patients are treated with CRS-HIPEC. Median survival in this population based group is 32.3 months.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Aged, Antineoplastic Agents/administration & dosage, Carcinoma/secondary, Colorectal Neoplasms/pathology, Combined Modality Therapy, Cytoreduction Surgical Procedures/trends, Female, Humans, Hyperthermia, Induced/trends, Infusions, Parenteral, Male, Middle Aged, Netherlands, Palliative Care, Peritoneal Neoplasms/drug therapy, Registries, Survival Rate, Time Factors
in
European Journal of Surgical Oncology
volume
41
issue
4
pages
71 - 466
publisher
Elsevier
external identifiers
  • scopus:84929942375
  • pmid:25680955
ISSN
1532-2157
DOI
10.1016/j.ejso.2015.01.018
language
English
LU publication?
no
additional info
Copyright © 2015 Elsevier Ltd. All rights reserved.
id
9f658e3c-0426-48e8-86bf-fb89e22d4a89
date added to LUP
2022-04-05 09:41:55
date last changed
2024-11-07 04:37:43
@article{9f658e3c-0426-48e8-86bf-fb89e22d4a89,
  abstract     = {{<p>BACKGROUND: Population-based data on the percentage of colorectal cancer (CRC) patients with synchronous peritoneal carcinomatosis (PC) being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are currently lacking. The current population-based study describes trends in the use of CRS-HIPEC in the Netherlands, one of the first countries where CRS and HIPEC was introduced.</p><p>METHODS: All patients diagnosed with synchronous PC of CRC between 2005 and 2012 were extracted from the Netherlands Cancer Registry (n = 4623). Patients with primary appendiceal cancer were excluded resulting in a study population of 4430 patients. Trends in the use of CRS-HIPEC over time were analyzed by means of a Cochrane-Armitage trend test. Survival proportions were calculated as the time between diagnosis and date of death or last follow-up (January 2014).</p><p>RESULTS: Of the total 4430 patients with synchronous PC, 297 (6.4%) underwent treatment with CRS-HIPEC. The proportion of colorectal PC patients receiving CRS-HIPEC increased significantly over time from 3.6% in 2005-2006 to 9.7% in 2011-2012 (p &lt; 0.0001). Overall median survival (MS) for patients treated with CRS-HIPEC was 32.3 months, whereas MS rates were respectively 12.6, 6.1 and 1.5 for months palliative chemotherapy with/without surgery, palliative surgery and best supportive care.</p><p>CONCLUSION: The proportion of patients diagnosed with synchronous PC from CRC treated with CRS-HIPEC has increased significantly over time and currently almost 10% of PC patients are treated with CRS-HIPEC. Median survival in this population based group is 32.3 months.</p>}},
  author       = {{Razenberg, L G E M and van Gestel, Y R B M and Creemers, G-J and Verwaal, V J and Lemmens, V E P P and de Hingh, I H J T}},
  issn         = {{1532-2157}},
  keywords     = {{Aged; Antineoplastic Agents/administration & dosage; Carcinoma/secondary; Colorectal Neoplasms/pathology; Combined Modality Therapy; Cytoreduction Surgical Procedures/trends; Female; Humans; Hyperthermia, Induced/trends; Infusions, Parenteral; Male; Middle Aged; Netherlands; Palliative Care; Peritoneal Neoplasms/drug therapy; Registries; Survival Rate; Time Factors}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{71--466}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Surgical Oncology}},
  title        = {{Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands}},
  url          = {{http://dx.doi.org/10.1016/j.ejso.2015.01.018}},
  doi          = {{10.1016/j.ejso.2015.01.018}},
  volume       = {{41}},
  year         = {{2015}},
}